S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:GERN

Geron (GERN) Stock Price, News & Analysis

$3.69
-0.04 (-1.07%)
(As of 04/19/2024 ET)
Today's Range
$3.55
$3.84
50-Day Range
$1.75
$3.77
52-Week Range
$1.64
$4.05
Volume
8.23 million shs
Average Volume
10.04 million shs
Market Capitalization
$2.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.33

Geron MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
44.5% Upside
$5.33 Price Target
Short Interest
Healthy
8.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.80
Upright™ Environmental Score
News Sentiment
0.63mentions of Geron in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.34) to ($0.14) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.38 out of 5 stars

Medical Sector

279th out of 907 stocks

Pharmaceutical Preparations Industry

121st out of 424 stocks

GERN stock logo

About Geron Stock (NASDAQ:GERN)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

GERN Stock Price History

GERN Stock News Headlines

Geron (NASDAQ:GERN) Rating Reiterated by Needham & Company LLC
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Geron (NASDAQ:GERN) Given Outperform Rating at Wedbush
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
GERN Mar 2024 3.500 put
GERN Apr 2024 1.000 put
GERN Apr 2024 1.500 call
Geron Corp.
MDGL Apr 2024 270.000 call
Stifel Nicolaus Reaffirms Their Buy Rating on Geron (GERN)
Why Is Geron (GERN) Stock Up 94% Today?
See More Headlines
Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/21/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GERN
CUSIP
37416310
Employees
141
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.33
High Stock Price Target
$6.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+44.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-184,130,000.00
Net Margins
-77,691.14%
Pretax Margin
-77,690.72%

Debt

Sales & Book Value

Annual Sales
$240,000.00
Book Value
$0.46 per share

Miscellaneous

Free Float
529,921,000
Market Cap
$2.02 billion
Optionable
Optionable
Beta
0.62
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. John A. Scarlett M.D. (Age 73)
    Chairman of the Board, President & CEO
    Comp: $1.53M
  • Dr. Andrew J. Grethlein Ph.D. (Age 60)
    Executive VP & COO
    Comp: $847.2k
  • Ms. Michelle J. Robertson (Age 56)
    Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer
  • Ms. Aron Feingold
    Vice President of Investor Relations & Corporate Communications
  • Mr. Scott Samuels
    Executive VP, Chief Legal Officer & Corporate Secretary
  • Ms. Shannon Odam (Age 49)
    Senior VP & Chief People Officer
  • Ms. Melissa A. Kelly Behrs (Age 60)
    Executive VP of Business Operations & Chief Alliance Officer
    Comp: $753.22k
  • Mr. Anil Kapur (Age 53)
    Executive VP of Corporate Strategy & Chief Commercial Officer
    Comp: $654.89k
  • Mr. Edward E. Koval (Age 62)
    Executive VP & Chief Business Officer
  • Dr. Faye Feller M.D. (Age 41)
    Executive VP & Chief Medical Officer

GERN Stock Analysis - Frequently Asked Questions

Should I buy or sell Geron stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GERN shares.
View GERN analyst ratings
or view top-rated stocks.

What is Geron's stock price target for 2024?

3 brokerages have issued 12-month target prices for Geron's shares. Their GERN share price targets range from $5.00 to $6.00. On average, they anticipate the company's stock price to reach $5.33 in the next year. This suggests a possible upside of 44.5% from the stock's current price.
View analysts price targets for GERN
or view top-rated stocks among Wall Street analysts.

How have GERN shares performed in 2024?

Geron's stock was trading at $2.11 on January 1st, 2024. Since then, GERN shares have increased by 74.9% and is now trading at $3.69.
View the best growth stocks for 2024 here
.

Are investors shorting Geron?

Geron saw a decline in short interest in March. As of March 31st, there was short interest totaling 46,660,000 shares, a decline of 8.4% from the March 15th total of 50,950,000 shares. Based on an average daily volume of 11,240,000 shares, the short-interest ratio is currently 4.2 days.
View Geron's Short Interest
.

When is Geron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GERN earnings forecast
.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) announced its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.06 million. Geron had a negative trailing twelve-month return on equity of 63.33% and a negative net margin of 77,691.14%. The business's quarterly revenue was down 77.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.10) earnings per share.

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Geron own?
Who are Geron's major shareholders?

Geron's stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.06%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis.
View institutional ownership trends
.

How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GERN) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners